Kymera Investor Presentation Deck
KT-413 Highly Active on Intermittent Dosing in Preclinical Models
Complete Tumor Regressions Associated with Robust IRAK4 and Ikaros/Aiolos Degradation for ~72h
+SEM
Tumor Volume (mm³)
Mean,
●
KYMERA
2500
2000
1500-
1000
500
Drug (Day 33)
IV vehicle
CC-220, 3 mg/kg, PO, QD x 21
KT-413, 10 mg/kg, IV, D1,2,21,22
7
14
21
28
Days After Start of Treatment
CC-220
KT-413 10 mg/kg
T/C%
(REG%)
9
(94)
CR
©2023 KYMERA THERAPEUTICS, INC.
0
5
PR
0
2
35
SD
0
In the OCI-LY10 MYD88MT xenograft model,
intermittent dosing of KT-413 induced strong
antitumor activity, including complete regressions.
Superior activity compared to IMID CC-220 alone
PD
7
0
10000
KT-413 Concentration
(ng/ml or ng/g)
1000
100
10-
1
0
•Tumor PK
48
HIH
Plasma PK
HH
96
Time (hr)
144
IRAK4
192
Ikaros
HHHHH
240
150
100
50
O
% of Vehicle Control
Single 10 mg/kg dose showed extended tumor
exposure and strong degradation of both IRAK4 and
IMID substrates that was maintained for least 72hr in
preclinical models
Target PD 80-90% Ikaros KD and 50-70% IRAK4 KD in tumor
for ≥72 hrs to achieve robust anti-tumor activity
PAGE 36View entire presentation